An EU based company bought their first drug for the US market. The drug had been in open distribution for several years. For a variety of reasons, they wanted to narrow the distribution to a single US distributor. In the process of doing this, they had concerns about making sure all patients had access to the drug, the healthcare providers would have a smooth transition, and the company would not lose sales or margin from returns, chargebacks, or lost sales during the transition.
Key to the transition was a coordinated communications plan both internal and external to the client. D2 also worked with client to secure a third-party logistics provider (3 PL) and highly qualified single distributor. This work included identifying target 3 PLs and distributors and selecting, contracting, and implementing a 3 PL and distributor. Since the EU parent company was active in the transition, education about nuances and unique aspects of the US pharmaceutical market was important to success.